- Home
- HYFT vs DXR Comparison
HYFT vs DXR Comparison
Compare HYFT & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFT | DXR |
|---|---|---|
| Founded | 1983 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 66.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYFT | DXR |
|---|---|---|
| Price | $1.95 | $12.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 330.0K | 4.3K |
| Earning Date | 12-15-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $18,214,531.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.78 | N/A |
| P/E Ratio | ★ N/A | $35.63 |
| Revenue Growth | ★ 18.33 | N/A |
| 52 Week Low | $0.27 | $6.55 |
| 52 Week High | $3.25 | $14.15 |
Technical Indicators
Market Signals| Indicator | HYFT | DXR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.48 |
| Support Level | N/A | $12.21 |
| Resistance Level | N/A | $13.02 |
| Average True Range (ATR) | 0.00 | 0.45 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 32.94 |
Price Performance
Historical ComparisonAbout HYFT MindWalk Holdings Corp. Common Stock
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.